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Abstract: In recent years, carbon nanomaterials have been intensively investigated for their possible
applications in biomedical studies, especially as drug delivery vehicles. Several surface modifications
can modulate the unique molecular structure of [60]fullerene derivatives, as well as their physic-
ochemical properties. For this reason, covalent modifications that would enable a greater water
solubilization of the fullerene buckyball have been rapidly investigated. The most exciting appli-
cations of fullerene nanomaterials are as drug delivery vectors, photosensitizers in photodynamic
therapy (PDT), astransfection or MRI contrast agents, antimicrobials and antioxidants. From these
perspectives, the glucose derivatives of [60]fullerene seem to be an interesting carbon nanomaterial
for biological studies. It is well-known that cancer cells are characterized by an increased glucose
uptake and it has also been previously reported that the glucose transporters (GLUTs) are overex-
pressed in several types of cancers, which make them attractive molecular targets for many drugs.
This study explored the use of a highly water-soluble glycofullerene (called Sweet-C60) in pancreatic
cancer studies. Here, we describe the PANC-1 cell proliferation, migration, metabolic activity and
glycolysis rate after incubations with different concentrations of Sweet-C60. The final results did not
show any influence of the Sweet-C60 on various cancer cellular events and glycolysis, suggesting that
synthesized glycofullerene is a promising drug delivery vehicle for treating pancreatic cancer.
Keywords: [60]fullerene; pancreatic cancer; drug delivery vehicles; glycofullerenes
1. Introduction
Recently, carbon nanomaterials have become increasingly popular in biological studies,
as can be seen by the oncology and clinical reports [1,2]. Moreover, some of them have
been officially approved for use in cancer treatment [3]. The [60]fullerene molecule (C60)
has also become a subject of interest due to the plethora of synthetic modifications that
increase its water solubility [4]. [60]fullerene is a spherical molecule that is shaped like a
regular icosahedron and is composed of 60 carbon atoms. As the [60]fullerene molecule
is insoluble in water, several synthetic approaches have been developed in the quest to
increase its bioavailability. Attaching polar functional groups to the [60]fullerene molecule
leads to increased solubility in aqueous media [5–7]. As described in our previous study,
high water solubility for fullerene nanomaterials can be obtained by using the Bingel–
Hirsch cyclopropanation reaction with designed malonic acid derivatives that have several
hydroxy, amino or carboxyl groups [8–10]. It is also worth mentioning that [60]fullerenes
can form lipid-like systems that are able to penetrate cell membranes thanks to their unique
spherical structure, which has a strong non-polar character.
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Moreover, the [60]fullerene derivatives can also be convenient scaffolds for delivering
drugs to targeted cellular sites [11] to target the nuclear pore complex, as well as the
tumor vasculature [12]. Other applications of buckyballs include photodynamic therapy
(PDT), the transfection of DNA and siRNA, MRI contrast agents, antimicrobials and
antioxidants [13–15]. Among others, [60]fullerene compounds with sugar functional
groups, which are also called glycofullerenes, are attractive nanomaterials for pancreatic
cancer studies due to their cellular localization inside the nuclear envelope, as well as
their ability to generate reactive oxygen species after illumination with blue LEDs [8]. Our
recent studies reported inhibitory activity for glycofullerenes on the non-receptor tyrosine
kinases, mainly Fyn and BTK, which are promising targets for anti-cancer therapies [16].
Furthermore, it is well-known that cancer cells are characterized by an increased glucose
uptake; hence, glucose-derived [60]fullerene nanomaterials may improve their location
in cancer cells and thus increase the effectiveness of targeted therapy [17]. It has been
reported that the glucose transporters (GLUTs) are overexpressed in several types of cancers,
which makes them attractive molecular targets for many drugs [18]. Here, we present
data that describe the cellular and molecular interactions of a photoactive [60]fullerene
derivative (Sweet-C60 Figure 1) in the presence of the pancreatic cancer cells PANC-1.
The synthesis of Sweet-C60 and its cellular localization in the pancreatic stellate cells has
already been described in our previously published report [8]. This study explored the
interactions of glycofullerene with the pancreatic cancer cells PANC-1. This type of tumor
is characterized by having the worst prognosis [19] and it is refractory to treatment with
high levels of mortality [20]. The average survival rate of patients with detected pancreatic
cancer does not exceed six months and only 3–6% of patients survive for five years [21,22].
Unfortunately, the frequency and number of deaths that are caused by pancreatic tumors
are gradually increasing [23]. The invasiveness and difficulty in treating pancreatic cancer
are caused by many factors, such as mutations in the genes [24]; microRNA regulation
disorders [25]; disorders in the signaling pathways, including apoptosis [26]; the presence
of cancer stem cells [27]; epithelial–mesenchymal transition; hypoxia [28,29]; and increased
angiogenesis [30,31].
Figure 1. Chemical structure of the water-soluble glycofullerene Sweet-C60.
Moreover, pancreatic cancer does not have any specific symptoms even after many
years, which is why it is usually only detected at an advanced stage [19]. Although
the research in recent years has contributed to a better understanding of genomic and
transcriptomic pancreatic cancer [32], treating this cancer is still a challenge. Additionally,
innovative and more effective treatment methods are still sorely needed, despite the
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advances in surgery, radiotherapy and chemotherapy. It seems that pancreatic cancer may
be a justifiable target for the use of glycofullerene nanomaterials due to its increased glucose
consumption, as well as the overexpression of the GLUTs. It has also been reported that
anti-Glut-1 antibodies may disrupt the Glut-1 transporter functions and decrease tumor
growth [33]. A high GLUT-1 expression was previously described in PANC-1 cells, which
showed higher levels of Glut-1 mRNA and protein levels than normal pancreatic cells. The
aforementioned experimental observation was verified using several biochemical assays
as well as patient-derived cell lines and PET experiments using 18F-deoxyglucose [34].
This article presents a study of the effects of the fullerene nanomaterial Sweet-C60 on
human pancreatic ductal adenocarcinoma (PANC-1). The results described here concern
the cellular proliferation, glycolysis, migration and metabolic activity of PANC-1 cells
after incubations with different concentrations of the [60]fullerene derivative. In addition,
the effects of the fullerene nanomaterial on the glucose transporter (GLUT-1) expression
were also studied. The study also attempted to determine the toxicity and multidirectional
effects of Sweet-C60 on pancreatic cancer cells.
2. Materials and Methods
2.1. Cell Culture
In this study we used PANC-1, human pancreatic ductal adenocarcinoma (ATCC®
CRL-1469™), which was purchased from Sigma-Aldrich. The cell line was cultured at
37 ◦C, 5% CO2, in DMEM media (Sigma-Aldrich, St. Louis, MO, USA), which had been sup-
plemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and penicillin
(50 U/mL) and streptomycin at a concentration of 50 ng/mL (Polpharma, Poland).
2.2. Glycofullerene Synthesis and Application
The Sweet-C60 was synthesized using the previously described methodology and
the fullerene nanomaterial was transferred through 0.45 µm membranes before being
lyophilized for the further cellular experiments [8]. The Sweet-C60 was used at concentra-
tions of 0.01 and 0.1 mg/mL. The solutions of the compound with various concentrations
were prepared in the culture medium. Different incubation durations (in a range from 2 to
120 h) were used depending on the experimental conditions.
2.3. Cell Counting Using a Hemocytometer
The cell proliferation rate was estimated by cell counting using a Bürker’s hemocy-
tometer (Heinz Herenz, Hamburg, Germany). The cells were seeded into six-well plates
(60,000 cells per well) and cultured in standard conditions for 48 h. Afterward, the cells
were treated with 0.01 or 0.1 mg/mL [60]fullerene derivative solution. The pancreatic
cancer cells were then incubated with 0.25% trypsin (Sigma-Aldrich, St. Louis, MO, USA)
for one minute. Next, the cells were removed from the suspension, diluted in a serum
culture medium and counted using the hemocytometer. The cells were counted every 24 h
for five days.
2.4. The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assays
The metabolic activity of the cells was measured using MTT tetrazolium dye (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich, St. Louis, MO,
USA). The cells were seeded into 12-well plates (20,000 cells per well) and cultured in
standard conditions for 48 h. The cells were then treated with 0.01 or 0.1 mg/mL of the gly-
cofullerene Sweet-C60 solution. After 48 or 120 h of incubation, the cells were supplemented
with an MTT stock solution (0.5 mg/mL) and incubated for 90 min. The formazan crys-
tals were dissolved in methanol (Avantor, Poland) and DMSO (Sigma-Aldrich, St. Louis,
MO, USA) solution (1:1). The absorbance was measured at a wavelength of 565 nm with
an InfiniteTM 200 Quad-4 MonochromatorTM plate reader (Tecan, Switzerland). Three
independent experiments were conducted.
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2.5. Wound-Healing Assay
The migration rate of the tested cells was determined using a wound-healing assay.
The cells were plated into six-well plates (200,000 or 50,000 cells per well) and cultured in
standard conditions for 24 h. Afterwards, the cells were treated with 0.01 or 0.1 mg/mL of
the [60]fullerene derivative solution. After 48 h (200,000 cells per well) or 120 h (50,000 cells
per well) of incubation, a wound (scratch) was made using a sterile tip. Pictures of the
wound were taken at set intervals until it was covered once again. The wound area was
analyzed using ImageJ (Wayne Rasband, National Institute of Health, Bethesda, MD, USA).
2.6. Cell Migration
Time-lapse images of the PANC-1 cells migration were taken using a Leica DMI6000B
microscope equipped with a Leica DFC360 FX CCD camera. The cells were plated into the
wells of 24-well plates and incubated with 0.01 or 0.1 mg/mL of a Sweet-C60 solution for 12
or 36 h. On the day of the measurements, the cell density was 5 or 10%. Time-lapse images
were taken for 12 h at five-minute intervals.
2.7. Western Blot
2.7.1. Procedure for the GLUT-1 Protein
The GLUT-1 protein assay was performed 48 and 120 h after the cells had been
incubated with 0.01 or 0.1 mg/mL of the [60]fullerene derivative solution. Cell lysis
was performed on ice using a lysing buffer that contained 1 mM of protease inhibitor
cocktail (Roche, Switzerland), 0.1 mM PMSF (Sigma-Aldrich, St. Louis, MO, USA), 1 mM
sodium orthovanadate (Sigma-Aldrich, St. Louis, MO, USA), an RIPA buffer (containing
nonylphenol ethoxylates, Thermo Scientific)) and SDS. The cells with the lysis buffer had
been incubated on ice for 10 min and then frozen at −80 ◦C. The cells were then thawed on
ice and centrifuged at 16,000 RPM for 10 min at 4 ◦C. The supernatant formed as a result
of centrifugation was transferred to newly prepared 1.5 mL Eppendorf tubes, which were
stored at −80 ◦C. The amount of protein was measured using Bicinchoninic Acid (BCA)
(Sigma-Aldrich, St. Louis, MO, USA) and Copper II sulfate (Sigma-Aldrich, St. Louis, MO,
USA). Proteins were run on Mini-Protecan® gels (4–15% of polyacrylamide, Thermo Fisher
Scientific, USA). The electrophoresis was carried out at an initial voltage of 90 V, which
was increased to 100 V. The proteins were transferred onto a nitrocellulose, blocked with
5% non-fat milk in a TBS-T buffer for 1.5 h and incubated with the primary antibodies
against GLUT-1 (ab115730, Abcam, Cambridge, UK) and vinculin (ab129002) (Abcam,
Cambridge, UK) at 4 ◦C overnight. Then, the membrane was washed three times in TBS-T
and incubated with the suitable secondary antibodies for 1.5 h. The signals were detected
using chemiluminescence using a SuperSignalTM West Pico PLUS Chemiluminescence
Substrate (Thermo Fisher Scientific, Waltham, MA, USA). Quantitative protein analysis
was performed using ImageJ (Wayne Rasband, National Institute of Health, Bethesda,
MD, USA).
2.7.2. Procedure for the HIF-1α, HO-1 and MMP-2 Proteins
The PANC-1 cell line was seeded in 3 cm Petri dishes (Nunc) at a density of 500,000
cells/well. After 24 h, 0 and 1 mg/mL solutions of Sweet-C60 at various concentrations
were added and the cells were incubated for the next 24 h. Next, the cells were harvested
via trypsinization, washed with PBS, centrifuged, suspended in a RIPA buffer containing
a Halt Protease Inhibitor Cocktail (final concentration of 25×) and a Halt Phosphatase
Inhibitor Cocktail (final concentration of 10×) along with 0.5 M EDTA (all from Thermo
Scientific, USA) and lysed for 20 min on ice. Then, the lysates were sonicated, centrifuged
at 10,000 rpm for 10 min at 4 ◦C, then the supernatants were collected. The protein
concentration was determined using a Micro BCA™ Protein Assay Kit (Thermo Scientific,
USA). Equal amounts of the proteins (20 µg) were electrophoresed on SDS-Page gels
(10% polyacrylamide + 0.1% SDS). After the electrophoresis the proteins were transferred
onto nitrocellulose membranes which were blocked in 5% non-fat milk (prepared in PBS
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containing 0.1% Tween-20 (TPBS)) for 1 h. After blocking, the membranes were incubated
with specific primary antibodies—HIF-1α (D2U3T) Rabbit mAb #14179, HO-1 (D60G11)
Rabbit mAb #5853, MMP-2 (D8N9Y) Rabbit mAb #13132 and GAPDH (14C10) Rabbit mAb
#2118—overnight at 4 ◦C. The next day the membranes were washed and incubated with
the horseradish peroxidase (HRP)-conjugated secondary antibodies (Anti-rabbit IgG, HRP-
linked Antibody #7074) for 1 h at room temperature. The antibodies were purchased from
Cell Signaling (Danvers, MA, USA). They were diluted 1:1000 in 5% milk in TPBS. Lastly, the
membranes were washed and incubated with a SuperSignal™ West Pico Chemiluminescent
Substrate (Thermo Scientific, Waltham, MA, USA). The chemiluminescence signals were
captured using a ChemiDoc™ XRS+ System (Bio-rad, Hercules, CA, USA). The experiments
were performed at least three times. The densitometric analysis was performed using
ImageJ 1.41 software.
2.8. Glycolysis Assay (Extracellular Acidification)
Extracellular acidification was detected using a Glycolysis Assay kit (Abcam, UK).
The cells were seeded into a 96-well black wall with clear flat bottom plates (30,000 cells
per well) and cultured in standard conditions for 24 h, after which the cells were treated
with 0.01 or 0.1 mg/mL of the Sweet-C60 solution. After 24 h, the cells were incubated with
reagents according to the manufacturer’s recommendations (ab197244). A CLARIO star
plate reader (BMG Labtech, Germany) was used to measure the extracellular acidification.
The signals were collected at 90-s intervals for about 120 min using excitation and emission
wavelengths of 340 and 615 nm, respectively.
2.9. Statistical Analysis
Statistical analysis was performed using Statistica (StatSoft. Inc., Tulsa, OK, USA).
Each experiment was repeated at least twice and between three and eight replicates were
performed in each of them. The final result was the mean value ± the standard error of the
mean (SEM). To determine the reliability of the differences in the comparative studies, the
values of given experiments were verified using a one-way analysis of variance (ANOVA).
The confidence interval was 95%, α = 0.05. In the event that p <0.05, the Newman–Keuls
test was carried out to determine which groups differed from each other.
3. Results and Discussion
3.1. The Changes in the Rate of Proliferation
Based on the pioneering publications of Wilson et al., we supposed that the water-
soluble [60]fullerene derivative might affect cellular pathways even though they are con-
sidered to be non-toxic without illumination [35–37]. Our previous studies showed that
Sweet-C60 had a negligible in vitro toxicity even at high doses (1 mg/mL) and localized
preferentially in the nucleus of the pancreatic stellate cells. Our cell proliferation study for
five consecutive days showed no significant change in dose-dependent proliferation rate.
The Kruskal–Wallis H (KW H) test results were p > 0.05 for all of the groups. By analyzing
the selected long-term points as depicted in Figure 2, it was determined that incubating the
PANC-1 cells with the glycofullerene led to a slightly slower proliferation rate (Figure 2B).
It was found that after 72 h of incubation with the [60]fullerene derivative solution at a dose
of 0.1 mg/mL, the relative number of PANC-1 cells was reduced to 77.8 ± 7.8% relative to
the control (Figure 2A). The one-way ANOVA analysis was p = 0.014 relative to the control
group. Next, a Newman–Keuls post hoc analysis was performed. A statistically significant
difference was found between the 0.01 mg/mL group and the 0.1 mg/mL group (p = 0.011).
Conversely, the incubation with Sweet-C60 for 120 h for both doses led to a decrease in
the number of cells relative to the control (Figure 2A). Correspondingly, the number of
cells after incubation with the glycofullerene at 0.01 mg/mL was 86.8 ± 4.1% compared
to the control, while the relative number of cells after incubation at 0.1 mg/mL was
84.1 ± 1.8% of control. The one-way ANOVA analysis relative to the control group was
p = 0.019. Statistically significant differences (Newman–Keuls post hoc analysis) were found
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between the control group and a concentration of 0.01 mg/mL (p = 0.026) and between
the control group and a concentration of 0.1 mg/mL (p = 0.023). The results showed that
after the 120-h incubation of the PANC-1 cells with the [60]fullerene derivative, the cell
number/mm2 decreased as the concentration increased (Figure 2B). The results that were
obtained after 24 h, 48 h and 96 h of incubation were not statistically significant. Moreover,
the results showed that the time required for the PANC-1 cell division after the treatment
with Sweet-C60 was slightly extended. The doubling time was 59.9 h for the untreated
cells (control cells), 66.2 h for the low dose and 66.6 h for the high dose, respectively. The
doubling times that were obtained were slightly higher than those presented in previous
reports [38,39]. The obtained growth factors and cell doubling times showed that the cells
that had been incubated with the highest (0.1 mg/mL) concentration of the [60]fullerene
nanomaterial proliferated most slowly (growth factor = 0.01042), whereas the control cells
proliferated the fastest (growth factor = 0.01156). The observed differences in the doubling
time may have been due to the cell maintenance conditions, such as nutrient access, the
surface area for growth and various stress factors. If there were significant differences in the
cell proliferation in the study groups, one could suppose that glycofullerene nanomaterial
has anti-tumoral cell division properties and is cytotoxic to them. Based on the current
data, we do not support such a hypothesis.
Furthermore, the mitochondrial activity was investigated in the PANC-1 cells after
their incubation with Sweet-C60 (Figure 2C). It was observed that treating the PANC-1 cells
with Sweet-C60 at a dose of 0.01 mg/mL led to an insignificant increase in the metabolic
activity. The number of metabolically active cells at a low dose of [60]fullerene derivative
increased to 106.3 ± 7.7% relative to the control (incubation for 48 h) and 105.1 ± 5.2%
(incubation for 120 h). In contrast, treating the PANC-1 cells with 0.1 mg/mL of Sweet-
C60 led to a decrease in the metabolic activity relative to the control group. The relative
metabolic activity was measured as 97.1 ± 6.2% (incubation for 48 h) and 90.2 ± 4.5%
(incubation for 120 h). For both incubation durations, there were no statistically significant
differences between the tested concentrations of the nanomaterial.
In the MTT metabolic test, the amount of formazan crystals formed was proportional
to the oxidative activity of the mitochondria of the cells and to the number of metabolically
active cells of a given population. It could therefore be concluded that the results obtained
for the MTT test were analogous to the rate of cell proliferation. Both tests were consistent
for the group of cells that had been treated with Sweet-C60 at a concentration of 0.1 mg/mL.
At the selected time points, the proliferation rate of the treated cells was slower and
the number of metabolically active cells was lower. However, for the concentration of
0.01 mg/mL, the number of metabolically active cells was higher in the control group.
Additionally, the metabolic activity slightly decreased with the incubation duration at both
concentrations. This phenomenon can be explained by the fact that, although the cells
were still metabolically active, their proliferation was slightly slower at selected points
over time. It can be assumed that if cells stop proliferating but are still metabolically active,
they begin to metabolize glucose through the oxidative phosphorylation pathway [40].
Hence, glycofullerene treatment could inhibit the PANC-1 cell proliferation by changing
the glucose metabolism pathways that are typical for the differentiated cells. On the other
hand, it cannot be ruled out that a slight slowdown in metabolism and a slight slowdown
in the proliferation over a long-term cell incubation might be caused by stress factors such
as nutrient depletion.
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Figure 2. The changes in the (A,B) proliferation and (C) mitochondrial activity in the PANC-1 cells after they had been
treated with different concentrations of the fullerene nanomaterial. Error bars are presented as (A,B) SD or (C) SEM. The
relative cell number indicates the cell number in the experimental group at the correct time point relative to the untreated
cell number at the same timepoint.
3.2. The Migration Rate and Wound Healing
The results depicted in Figure 3A–D were obtained for the wound-healing test and
showed how a wound surface might decrease (100% was the surface at the time the wound
was made) depending on the duration (x-axis). After 48 h of incubation with Sweet-C60,
the changes in the rate of wound healing were observed between two and four hours
of measurement (in the initial phase, the rate of migration was steady at all levels). It
was shown that, in the last hour of measurement (25.5 h), the wound surface decreased
to 54.1 ± 4.8% of its initial surface area in the control group, 66.6 ± 6.4% for the group
that had been treated with Sweet-C60 at a concentration of 0.01 mg/mL and 48.5 ± 4.4%
in the 0.1 mg/mL group. However, for the incubation for 120 h, in the last hour of
measurement (22 h), the remaining wound area was 69 ± 3.0% for the non-treated group,
69.5 ± 1.6% for the 0.01 mg/mL group and 74.9 ± 1.0% for the 0.1 mg/mL group. Based
on the determined trend lines and their equations, it was shown that, for both incubation
durations (48 h and 72 h), the control group wound healed the fastest (untreated cells),
while the slowest wound healed when cells had been treated with the Sweet-C60 at a
dose of 0.01 mg/mL. The coefficient α for the linear decreasing function for the control
group and doses of 0.01 mg/mL and 0.1 mg/mL of Sweet-C60 were −0.0182, −0.0141 and
−0.0162, respectively (for 48-h incubation) and −0.0132, −0.0119 and −0.0120 (for 120-h
incubation), respectively. To summarize, when the proliferation time was considered, the
wound-healing assay did not provide a clear answer about the impact of Sweet-C60 on the
pancreatic cancer cell migration. It has been postulated by some authors that PANC-1 cells
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have motility and they appear to migrate mainly as single cells, which is why a time-lapse
migration analysis was performed in the next step [39]. Here, it was clearly observed that
the PANC-1 cells had a very limited migration. Both the cells in the control group and
the cells that had been incubated with Sweet-C60 (different concentrations and incubation
durations) did not show any significant movement, displacement or polarity in any of
the tested conditions. The representative data is presented in Supplementary Movie S1
(PANC-1 control) and Movie S2 (PANC-1 that was treated with Sweet-C60).
Figure 3. The wound-healing test was performed for the PANC-1 cells that had been incubated with Sweet-C60 for (A) 48 h
and (B) 120 h. The cells were prepared at different densities in order to manage different incubation times: (A) a high cell
density of 200,000 cells and (B) 50,000 cells. Error bars presented as SD. (C) A representative image of the wound scratch
made in the PANC-1 colony; (D) a representative image of the PANC-1 cells that were used for a time-lapse movement
analysis under a Leica microscope. The gray bars on the x-axis (A,B) indicate time periods.
Moreover, it has also been postulated that glucose concentration might be an important
factor for cancer cell migration [41]. That is why the observation that Sweet-C60 did not
influence cell mobility is noteworthy, as it makes it a promising nanoscale drug delivery
tool for anti-cancer studies
3.3. Expression of the Glucose Transporter Protein (GLUT-1)
Expression of the GLUT-1 protein in the PANC-1 cells was investigated using the
Western blot technique and is represented as its ratio to vinculin (the reference protein,
Figure 4). The data is represented as the mean± SEM, n = 3. The cancer cells were
incubated in a media with a different concentrations of the fullerene nanomaterial and
with no [60]fullerene as the control. The cells were incubated in standard conditions
for 48 and 120 h without changing the media. Due to the increased number of cells
and decreasing nutrient supply during the incubation time, the expression of GLUT-1
significantly increased over time, especially in the control group (p = 0.0495, Kruskal–
Wallis test). Interestingly, the level of the GLUT-1 protein did not change significantly
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during the incubation with Sweet-C60. At the 48th hour after the incubation with the
fullerene nanomaterial, there was a slight increase of GLUT-1 for both of the Sweet-C60
concentrations—this effect could be explained by the increased possibility for the cells
to uptake additional glucose. What is more, after 120 h of incubation, there was a slight
increase of GLUT-1 protein for the 0.01 mg/mL concentration, but there was no change
of GLUT-1 in the cells that had been incubated with the 0.1 mg/mL concentration of the
glycofullerene. These results suggest that a high concentration of Sweet-C60 in cells that
were grown in a medium did not induce cancer cells to express high GLUT-1 concentration
over the incubation period.
Figure 4. The effects of the fullerene nanomaterial Sweet-C60 on the activity of GLUT-1 protein. Error bars are presented
as SD.
3.4. Expression of the Proteins Related to Cancer Cell Migration
The cancer nanotechnology literature includes descriptions of several interactions
between different types of water-soluble [60]fullerenes (cationic, neutral or anionic) that
have enzymes that could be crucial for anti-cancer studies. We focused here on three
different proteins, MMP-2, HIF-1 and HO-1, which have been previously reported and
could be inhibited/activated after the cancer cells had been incubated with different
fullerene nanomaterials [42,43]. The influences of the studied fullerene nanomaterial on
the MMP-2, HIF-1 and HO-1 proteins were studied using the Western blot technique after
24 and 72 h of incubation (Supporting Information, Figure S1). There were no significant
changes to the studied proteins in the tested conditions. This observation indicates that
the tested compound could be used as a convenient vehicle for drug delivery for treating
pancreatic tumors.
3.5. Glycolysis Assay
GLUT-1 is a well-known protein that is involved in regulating the cell glycolysis
cycle, which has been demonstrated on cancer cell lines such as prostate and breast tu-
mors [44]. Moreover, an enhanced glycolysis (Warburg effect) is one of cancer’s hallmarks;
it is associated with extremely aggressive cancers and is used for developing targeted
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cancer nanotechnologies [45]. For example, cancer cells in the hypoxic areas often switch
their metabolism to the glycolysis pathway. Our previous report described the effects
of Sweet-C60 on the OH-1 levels and also indicated that the induction of autophagy took
place after incubating the PANC-1 cells with Sweet-C60 [16]. The autophagy process has
been described as being connected with glycolysis in pancreatic cancer [46]. Here we
observed a slight increase in the glycolysis rates (Figure 5), which were measured by
the extracellular acidification rate (ECAR) for the higher concentration of glycofullerene
(0.1 mg/mL (p = 0.08)). These results suggest that while additional glucose availability
might be related to an enhanced glycolysis, the possible effect is not strong and should not
have any influence on migration of cells.
Figure 5. The effects of water-soluble glycofullerene Sweet-C60 on glycolysis in the PANC-1 cells. Error bars are presented
as SD.
4. Conclusions
The results showed that higher doses of the fullerene nanomaterial Sweet-C60 do not
have a significant influence on cell proliferation, metabolic activity or migration potential.
Although a slight increase in the glycolysis process is possible for the higher concentrations
of Sweet-C60, based on all of the presented results, it does not cause an increased migration
of pancreatic cancer cells. Moreover, the presented data indicates that Sweet-C60 could be a
promising drug delivery vehicle due to its lack of influence on cell migration, proliferation
and metabolism while, at the same time, as is presented in our previous study, accumulating
in the PANC-1 cells. What is also important is that the lower doses of this nanomaterial
led to a decrease in the rate of proliferation that was accompanied by an increase in their
metabolic activity. This effect may indicate an inhibition of the proliferation as a result of the
changes in the glucose metabolism due to cell differentiation. Moreover, the overexpression
of the GLUT-1 protein after incubation with Sweet-C60 was also demonstrated. This effect
may lead to sensitizing the cells to targeted therapies due to an increased glucose demand.
Nanomaterials 2021, 11, 513 11 of 13
The final results suggest potential applications of water-soluble [60]fullerenes in biomedical
research, specifically in cancer nanotechnology.
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S2: PANC-1 cells movements after the treatment with Sweet-C60.
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